Dr Michael Allen Eddy, PHARMD | |
520 W Bertrand Ave, Saint Marys, KS 66536-1695 | |
(785) 437-2967 | |
Not Available |
Full Name | Dr Michael Allen Eddy |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 520 W Bertrand Ave, Saint Marys, Kansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598065112 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 1-13105 (Kansas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Michael Allen Eddy, PHARMD 520 W Bertrand Ave, Saint Marys, KS 66536-1695 Ph: (785) 437-2967 | Dr Michael Allen Eddy, PHARMD 520 W Bertrand Ave, Saint Marys, KS 66536-1695 Ph: (785) 437-2967 |
News Archive
Approximately 57.2 million people under the age of 65—more than one in five (22.4 percent) of America's non-elderly population—have a diagnosed pre-existing condition that could lead to a denial of coverage in the individual health insurance market, according to a report released today by the consumer health organization Families USA.
The first MinuteClinic walk-in medical clinics in central Georgia have opened inside two CVS/pharmacy stores in Macon and one in Warner Robbins.
A study performed by the team of Dr. Nabil G. Seidah, Director of the Biochemical Neuroendocrinology Research Unit at the IRCM, shows for the very first time that the degradation by PCSK9 of the LDLR receptor, which is responsible for removing the bad cholesterol (LDL-cholesterol) from the bloodstream, may be inhibited by a third protein, annexin A2.
Many patients with chronic hepatitis B are deficient in their understanding of the lifelong disease and often do not comply with the drug regimens necessary to control it, according to a new UCLA survey that suggests improved patient involvement in disease management decisions could be the key to fixing this problem.
Teva Pharmaceutical Industries Ltd. announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.
› Verified 3 days ago